New Clinical Evidence Underscores Strong Adoption
of MolecuLight's Wound Imaging Platform to Improve Clinical
Decision-Making and Achieve Outstanding Patient Outcomes
TORONTO and ORLANDO,
Fla., May 14, 2024 /PRNewswire/ - MolecuLight
Inc., the pioneer in point-of-care fluorescence imaging for
real-time detection of elevated bacterial loads in wounds, proudly
announces the presentation of findings from multiple MolecuLight
studies in nine clinical posters at the Symposium on Advanced Wound
Care (SAWC) Spring 2024. These studies feature new data
demonstrating enhanced diagnostics, targeted debridement, improved
healing outcomes, and increased patient engagement facilitated by
MolecuLight devices. Notably, one of these posters, recognized as
the top-scoring abstract, introduces an innovative upcoming device
feature: thermal imaging. The international conference, taking
place from May 14 - 18, 2024, in
Orlando, Florida, stands as one of
the largest multidisciplinary meetings of wound care professionals
globally.
"We are delighted to witness the ongoing surge in the adoption
of our technology across the US and abroad, which has resulted in a
significant presence at SAWC Spring, further confirming the
value of MolecuLight as seen by clinicians", remarks Anil Amlani,
CEO of MolecuLight. "The widespread adoption of MolecuLight can be
attributed to the unique capability of our devices to accurately
detect the location and load of bacteria that can lead to
infections resulting in better patient outcomes. It has swiftly
become an indispensable asset in wound care practices, seamlessly
integrated across various healthcare settings including HOPD, ASC,
Wound Care Centers, SNFs, Long Term Care, Podiatry, and Home
Health."
"It is an honor to present some of our work on bacterial
fluorescence imaging", says Dr. Charles
Andersen, Chief of Wound Care Service at Madigan Army
Medical Center in Tacoma WA, USA,
and a seasoned vascular surgeon and wound care expert. "The
findings we are presenting at this iteration of SAWC show how this
device has put forward solutions to longstanding debates in wound
care like: Do you debride patients with pyoderma gangrenosum? And
if so, how far do you debride?" Dr. Charles
Andersen continues, "MolecuLight has enabled selective and
targeted debridement and supports more rapid healing, but there is
much more to the story. It is a value-add for the education of
patients, empowering them and helping them to lead their wound care
journey. And, now we're also investigating how fluorescence and
thermal imaging can act as synergistic partners. We describe this
utility in a multi-site clinical study that earned the honor of Top
Scoring Poster. Several clinical applications where fluorescence
imaging was already very useful were further complemented by the
addition of this new feature, which speaks to MolecuLight's
versatility and continued effort to break the barriers that prevent
our patients from healing".
The clinical presentation and posters featuring the
MolecuLight i:X and DX from SAWC Spring
2024 are as follows:
- Poster CS-006, "Advanced Wound Care of Pyoderma Gangrenosum
Through Fluorescence-Guided Debridement", presented by Dr.
Charles Andersen;
- Poster CS-007, "Source Control of Bacteria in Wound
Associated Cellulitis Prevents Progressive Cellulitis with its
Associated Complications and the Overuse of Antibiotics",
presented by Dr. Charles
Andersen;
- Top-Scoring Poster CS-009 (RPT-002) and Presentation,
"Enhancing Wound Care: The Synergistic Potential of Multi-modal
Fluorescence and Thermal Imaging", presented by Dr.
Charles Andersen;
- Poster CS-133, "Making a Difference in Patient Engagement
& Wound Outcomes with Innovative "Point of Care" Imaging in
the Mobile Wound Care Setting", presented by Dr. Ali Saberi;
- Poster CR-005 (RPT-005), "Patient Engagement and
Satisfaction are Enhanced by Incorporating Fluorescence Imaging
into a Wound Care Practice", presented by Dr. Charles Andersen;
- Poster CR-029, "Bacterial fluorescence imaging improves
chronic wound biofilm detection over standard clinical assessment
and blotting", presented by Dr. Laura
Jones-Donaldson;
- Poster PI-001, "Enabling Proactive Intervention:
Understanding Chronic Inhibitory Bacterial Loads through
Fluorescence Imaging and Why It Matters", presented by Dr.
Raymond Abdo;
- Poster PI-016, "The Predictive Power of Bacterial
Fluorescence Imaging", presented by Dr. Laura Jones-Donaldson; and
- Poster PI-026, "Using Bacterial Fluorescence Imaging to
Evaluate & Improve the Effectiveness of Wound Hygiene",
presented by Dr. Alisha
Oropallo.
In addition to the clinical posters and presentations
at SAWC Spring 2024, the MolecuLight
i:X® and DX™ imaging devices
will be available for demonstration in the MolecuLight booth #312
in the Exhibition Hall.
The MolecuLight i:X® and
DX™ are the only CLASS II FDA cleared imaging devices for
the real-time detection of elevated bacterial burden in wounds.
With unmatched clinical evidence including 95 peer-reviewed
publications with over 3000 patients, they are used by leading
wound care facilities globally.
About MolecuLight
Inc.
MolecuLight Inc. is a privately owned medical imaging company
with global presence that offers fully commercialized point-of-care
digital wound measurement and real-time bacterial detection through
fluorescence imaging platform technology.
MolecuLight's suite of commercial devices,
which include the MolecuLight i:X® and
DX™ fluorescence imaging and digital wounds measurement
systems and their accessories, have scientifically proven
capabilities that enhance wound care practices and outcomes across
all places of service. MolecuLight procedures performed in
the United States benefit from an
available reimbursement pathway which includes two CPT®
codes for physician work to perform "fluorescence
imaging for bacterial presence
location, and load" and facility
payment for Hospital
Outpatient Department (HOPD) and Ambulatory Surgical
Center (ASC) settings through an Ambulatory Payment Classification
(APC) assignment.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculight-clinical-research-featured-at-the-upcoming-sawc-spring-2024-conference-302144382.html
SOURCE MolecuLight